Skip to Content

Delafloxacin Pregnancy and Breastfeeding Warnings

Delafloxacin is also known as: Baxdela

Medically reviewed by Last updated on Jan 7, 2019.

Delafloxacin Pregnancy Warnings

The manufacturer makes no recommendation regarding use during pregnancy.

US FDA pregnancy category: Not assigned.

Risk summary: Insufficient data available on use of this drug in pregnant women to inform a drug-related risk.

Animal studies have revealed evidence of fetotoxicity but failed to reveal evidence of teratogenicity or fetolethality. After oral administration to rats during organogenesis, maternal toxicity and reduced fetal body weights were seen at the highest dose (1600 mg/kg/day) and delayed fetal ossification was observed at all doses; no malformations were observed up to the highest dose (about 7 times the estimated human plasma exposure [based on AUC]). At the highest IV dose (120 mg/kg/day; estimated about 5 times human plasma exposure [based on AUC]) in a pre-postnatal study, pregnant rats showed slightly lower body weights and slightly longer gestation length than controls; effects on pups included increased mortality during lactation, small stature, and lower body weights (learning, memory, sensory function, locomotor activity, developmental landmarks, and reproductive performance were not affected); the No Observed Adverse Effect Level (NOAEL) for maternal toxicity pup development was 60 mg/kg/day (about 580 mg/day IV for 60 kg patient [just below clinical IV dose]). There are no controlled data in human pregnancy.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

See references

Delafloxacin Breastfeeding Warnings

Cartilage erosion and arthropathy have been observed in immature animals giving rise to concern over toxic effects in the developing joints of nursing infants; however, some studies suggest risk is low. Absorption of fluoroquinolones in milk may be blocked by the calcium in milk; data insufficient to prove or disprove.

Use is considered acceptable; however, an alternate agent with safety information available is preferred.

Excreted into human milk: Unknown
Excreted into animal milk: Yes

-Developmental and health benefits of breastfeeding should be considered as well as the mother's clinical need for this drug.
-The effects in the nursing infant are unknown; potential side effects in the breastfed child due to this drug or the mother's underlying condition should be considered.

See references

References for pregnancy information

  1. "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.

References for breastfeeding information

  1. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):
  2. "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.